Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41564-020-00789-5 http://scihub22266oqcxt.onion/10.1038/s41564-020-00789-5 32908214!ä!32908214 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Microbiol 2020 ; 5 (10): 1185-1191 Nephropedia Template TP {{tp|p=32908214|t=2020. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies |pdf=|usr=}}{{32908214}} gab.com Text Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies JO: Nat Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=32908214 #FOAvip Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2. Twit Text FOAVip Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies ????Nat Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=32908214 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32908214 #FOAvip English Wikipedia <ref>{{Cite pmid|32908214}}</ref> Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies #MMPMID32908214 Lee WS; Wheatley AK; Kent SJ; DeKosky BJ Nat Microbiol 2020[Oct]; 5 (10): 1185-1191 PMID32908214show ga Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2. |*Antibody-Dependent Enhancement/immunology[MESH] |*Betacoronavirus/immunology[MESH] |Animals[MESH] |Antibodies, Monoclonal/administration & dosage[MESH] |Antibodies, Neutralizing/administration & dosage[MESH] |Antibodies, Viral/administration & dosage/immunology[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/drug therapy/*immunology/prevention & control/*therapy[MESH] |Humans[MESH] |Immunization, Passive/adverse effects[MESH] |In Vitro Techniques[MESH] |Models, Immunological[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*immunology/prevention & control/*therapy[MESH] |Respiratory Tract Diseases/etiology/immunology[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Safety[MESH]Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies (epmc).pdf DeepDyve Pubget Overpricing